SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
                       THE SECURITIES EXCHANGE ACT OF 1934

                                 Date of Report
               (Date of earliest event reported): February 3, 2004

                           ARIAD PHARMACEUTICALS, INC.
                           --------------------------
             (Exact Name of Registrant as Specified in its Charter)


       Delaware                        0-21696               22-3106987
       --------                        -------               ----------
(State or Other Jurisdiction   (Commission File Number)  (I.R.S. Employer
of Incorporation)                                        Identification No.)


                              26 LANDSDOWNE STREET
                         CAMBRIDGE, MASSACHUSETTS 02139
              (Address of principal executive offices and zip code)


               Registrant's telephone number, including area code:
                                 (617) 494-0400





ITEM 7.    FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.

           (c) Exhibits.

           99.1  The Registrant's Press Release dated February 3, 2004.

           This Press Release is being furnished pursuant to Item 12 of this
           Current Report on Form 8-K and shall not be deemed "filed" for
           purposes of Section 18 of the Securities Exchange Act of 1934 (the
           "Exchange Act") or otherwise subject to the liabilities of that
           Section, nor shall it be deemed incorporated by reference in any
           filing under the Securities Act of 1933 or the Exchange Act.


ITEM 12.   RESULTS OF OPERATIONS AND FINANCIAL CONDITION

           On February 3, 2004, ARIAD Pharmaceuticals, Inc. announced its
           financial results for the three months, and for the year, ended
           December 31, 2003. A copy of the Press Release is furnished
           pursuant to this Item 12 as Exhibit 99.1 to this Current Report on
           Form 8-K.


                            SIGNATURES

         Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.


                              ARIAD PHARMACEUTICALS, INC.



                              By:    /s/ Edward M. Fitzgerald
                                     ------------------------
                                     Edward M. Fitzgerald
                                     Senior Vice President and
                                      Chief Financial Officer


Date:    February 3, 2004




                                       2





                                  EXHIBIT INDEX

Exhibit
Number      Description                                   Sequential Page Number
- -------     -----------                                   ----------------------

99.1        The Registrant's Press Release dated February 3, 2004.       4




                                       3